To investigate the rate of asymptomatic recurrence of stage 1 endometrioid endometrial cancer and assess the role of routine hospital follow-up after treatment.
We performed a retrospective case-note review study of women who were diagnosed with stage 1 endometrioid endometrial adenocarcinoma at Queen’s Hospital, Romford, between January 2008 and December 2016.
We included 299 patients with a median follow-up period of 44.4 months. All the patients underwent total hysterectomy and bilateral salpingo-oophorectomy. Adjuvant radiotherapy was offered to the patients subsequent to discussions in the multidisciplinary team meeting in accordance with the risk stratification criteria. There was no significant correlation between the risk factors and disease recurrence. In total, 11 patients presented with recurrent disease with original staging: 1a, n=6/199; and 1b, n=5/100. Four patients presented with vaginal bleeding due to vault recurrence and one patient with abdominal pain due to pelvic mass. Locoregional recurrence was an incidental finding in two other patients. Four patients presented with symptomatic distant metastases to the lung (n=2), liver (n=1), and bone (n=1). No asymptomatic recurrences were identified on routine follow-ups, despite several hospital appointments and clinical examinations. The recurrence rate for patients with stage 1a and 1b, grade 1, and grade 2 disease was 3.53%, and that for patients with stage 1a, grade 1, and grade 2 disease was 2.7%.
Routine clinical examinations have a low yield in finding recurrence in asymptomatic women and should be questioned for their value, considering the limited resources of the National Health Service (NHS). Larger studies are required to support a stratified follow-up, which will include telephone and patient-initiated follow-up.
Endometrial cancer is the most common gynecological cancer in the developed world, and its increasing incidence [
Low-grade stage 1 endometrioid endometrial adenocarcinoma has a quoted recurrence rate of 1–3%, and it is uncommon for recurrences to be asymptomatic and detected solely on follow-up examination [
We present a comprehensive retrospective review of all the patients who were treated surgically for stage 1 endometrioid endometrial cancer and had their diagnosis at our gynecological oncology unit between January 2008 and December 2016. This study aimed to ascertain the clinical presentation of disease recurrence and evaluate the role of routine hospital follow-up in the detection of cancer recurrence, motivated by the favorable impact of an increasing number of hospitals in the UK adopting patient-initiated follow-up of cancer patients.
All the patients who had stage 1 endometrioid adenocarcinoma of the endometrium, diagnosed at Queen’s Hospital, Romford, UK, from January 2008 to December 2016, were identified from the pathology database. Women with other histological types of cancer of the endometrium, such as serous, clear cell, and carcinosarcoma, were excluded. Patients who were not treated surgically were excluded. This review of clinical service provision/audit (as defined by the Health Research Authority) was registered at the Queen’s Hospital Clinical Audit Department.
Data was extracted from online medical records, written case notes, histology, and radiology reports. Demographics and risk factors included age, ethnicity, body mass index (BMI), medical comorbidities of hypertension, diabetes, previous history of breast cancer, and tamoxifen use. Clinical presentation and tumor data (endometrial thickness, histology results, staging) were obtained, along with the number of routine follow-up appointments attended, clinical presentation of recurrence including the treatment received by these patients, and the outcome.
Preoperative staging was based on magnetic resonance imaging (MRI) findings and confirmed by histology. Low-risk groups (grade 1–2, presumed stage 1a on imaging and grade 1, and presumed stage 1B on imaging) underwent surgery at Queen’s hospital. High-risk groups (grade 2 and presumed stage 1B) on preoperative imaging or any grade 3 endometrial endometrioid adenocarcinoma) were treated surgically at the referral gynecological oncology center and received postoperative follow-up at Queen’s hospital. Pelvic lymphadenectomy was not routinely performed according to our protocol. If the MRI pelvis showed enlarged lymph nodes or lymphadenopathy (suspicion of involvement), the lymph nodes were removed surgically. According to risk stratification (low risk, intermediate risk, and high risk), the patients were offered adjuvant radiotherapy (external beam radiotherapy, adjuvant brachytherapy, or both), depending on the final histological stage, the grade, and the presence of adverse prognostic factors, such as lymphovascular space invasion, after discussion in a multidisciplinary team (MDT) meeting. Immunohistochemistry was not a part of the risk stratification process during the time period that is being examined in the present study.
All the patients treated for stage 1a, grade 1 endometrioid endometrial adenocarcinoma were offered 3–5 years of hospital follow-up, entailing an appointment with a clinician every 4 months for the first year and every 6 months thereafter, as per the hospital policy. The appointment routinely involved questioning about the symptoms and clinical examination including that of the pelvis and the abdomen. Further investigations were requested if recurrence was suspected. Patients with stage IB or high-grade disease were offered the same follow-up regime for 5 years, and then transitioned to the purview of their general practitioner.
Data was analyzed using IBM SPSS Statistics Version 24.0.0.0 for Macintosh “macOS” (IBM Corp., Armonk, NY, USA). Univariate analyses of the time to recurrence were performed with the time of first treatment as the entry date and the occurrence of recurrence, defined as the event, as the date of the follow-up appointment with clinical evidence of recurrence (symptoms/signs of recurrent disease). Fisher’s exact test was used for comparisons between categorical variables, and in this case, the presumable risk factors divided into categories were considered as independent variables, and the dependent variables were defined as recurrence or not. Multivariate analyses were also performed to predict recurrence in different groups that have been considered important in the literature for predicting recurrence, specifically the stage and grade of the primary disease. The mean and median values were calculated.
Over a period of 9 years, 328 patients were diagnosed with stage 1 endometrioid endometrial adenocarcinoma of various grades (
The mean age at diagnosis was 62 years (range 32–91 years). In total, 32 patients died: 6 due to endometrial cancer, 18 due to other known causes, and the cause of death remained unidentified in eight patients. Out of these eight patients, 5 were still under follow-up with no evidence of disease recurrence, and the remaining 3 had completed follow-up for endometrial cancer and were discharged. The median follow-up period for the cohort was 44.4 months (range 7.2–90.4 months).
Characteristics of the patients are described in
Most patients (n=199, 66.6%) had stage 1a disease, and 100 of them (33.4%) had stage 1b disease. Grade 1 cancer was seen in 219 patients, while 64 patients had grade 2 cancer. Of the 16 patients with grade 3 cancer, one patient had recurrence. Adjuvant radiotherapy was recommended for 81 patients following an MDT discussion. Of these, 1 patient declined radiotherapy (stage 1a, grade 3) and another patient was unfit for radiotherapy due to multiple comorbidities. Both these patients experienced recurrence of the disease.
Recurrence of endometrial cancer was seen in 11 patients (3.7%) and the details are described in
Symptoms at presentation usually correlate with the site of recurrence. Four women presented with signs and symptoms of distant recurrence: shortness of breath due to lung metastases (n=2), severe hip pain due to bone metastasis (n=1), and jaundice due to liver metastases (n=1). Almost all the women presenting with distant metastases died of disease progression. A woman who presented with a solitary lung metastasis, 50 months after primary surgery for stage 1a grade 1 endometrial cancer and underwent left upper lobectomy, was still in remission with letrozole hormonal treatment at the time of the last follow up appointment.
Four women experienced vaginal bleeding due to vault recurrence. Three of them presented with vaginal bleeding and had contacted the department, and one was experiencing vaginal bleeding but waited for a routine clinic appointment to discuss her symptoms. Three of the women with vaginal vault recurrence received treatment with curative intent, and all of them had further relapse several months later (range 18–32 months). One woman had concurrent gastric cancer and died later.
One woman presented with abdominal pain, bloating, and fatigue, with a computerised tomography (CT) scan revealing a pelvic peritoneal mass, enlarged lymph nodes, and a hydroureter. This case was identified on follow-up in a symptomatic patient who waited for a routine follow-up appointment to report her new symptoms.
Recurrence was an incidental finding in two women. One woman was admitted with stroke and had CT of the chest, abdomen, and pelvis, with peritoneal malignancy in the pelvis, which was presumed to be a recurrence of endometrial cancer. Finally, vaginal vault recurrence was an incidental finding on MRI performed in a woman with hip pain.
The median time from treatment to the first recurrence was 22 months (range 5–60 months post-treatment). The mean time was 28.5 months. There was no significant correlation between the risk factors and disease recurrence or between the risk factors and the time between treatment and recurrence. Age, parity, menopausal status, BMI, past and current use of hormone replacement therapy, history of diabetes, and hypertension were included as the risk factors. The history of breast cancer, tamoxifen use, and the grade and stage of primary cancer were examined, and no statistically significant difference was found. The correlation of risk factors with recurrence was not within the scope of the current study and would require more detailed analysis to arrive at definite conclusions.
Our study found that traditional hospital follow-up played a limited role in the detection of disease recurrence. In 2 cases, the routine follow-up approach had a potential adverse effect on the patients, as both of them.
Waited for their routine clinic appointment scheduled a few weeks after the onset of symptoms. This illustrates the importance of the patients’ education and understanding of the signs and symptoms of disease recurrence and the need for open communication pathways for the patient to initiate, if symptoms arise. In total, five patients had vaginal vault recurrence, four of them had bleeding, and one was asymptomatic. Two other patients experienced locoregional recurrence. None of these cases of recurrence were detected during the routine follow-up appointments and were either missed on clinical examination or became evident during the interval between the appointments. Furthermore, four patients with recurrence presented with distant metastatic disease, which was not detected during the routine follow-up appointments, questioning the effectiveness of routine pelvic examination for patients without vaginal bleeding.
In our study, none of the patients with early-stage endometrial cancers had asymptomatic recurrence identified during the routine follow-up appointments. A recent Danish study by Jeppesen et al. [
Regarding the pattern of recurrence in our study, four patients had distant recurrence (1.3%) and 7 (2.3%) had recurrence in the pelvis, vaginal vault, or pelvic peritoneum (locoregional). Recent studies have reported variable patterns depending on the risk factors, mainly on the histological subtype and initial staging [
The largest study till date reviewed all the patients with endometrial cancer in Germany between 2000 and 2016 [
The studies by Jeppesen et al. [
The NHS is facing increasing financial pressures, with a need to develop more cost-effective ways of caring for patients to achieve sustainability in the future [
There is a shift to an alternative, more cost-effective follow-up for women with low risk for recurrence, early stage, endometrial cancer; examples being a nurse-led telephone follow-up [
Patient-initiated follow-up (PIFU) aims to individualize patient care based on the risk of recurrence and holistic needs, while simultaneously optimizing resources. A recent UK study reported that PIFU is well received by women treated for endometrial cancer, although younger women (median age 57 years) initiated more contact with the health care staff, indicating that they needed a higher level of support [
The NCSI 2013 advises that individuals are assessed to determine the tier of follow-up that would best meet their needs. Individuals deemed at low risk of recurrence and late effects (physical and psychosocial) are encouraged to opt for self-management, those at medium risk receive planned, coordinated care, and those at high risk receive complex care from specialist services. MDT review is required to triage the patients according to low, intermediate, or high risk of cancer recurrence [
A recent randomized control trial comparing traditional hospital follow-up and patient-initiated follow-up found that women in the patient-initiated group had significantly higher levels of fear of cancer recurrence than women receiving traditional hospital follow-up [
This has become even more relevant in the current time of the COVID-19 pandemic, as more patients have been followed-up with telephone consultations in all hospitals across the UK.
This study was limited by data availability due to the retrospective nature of this study. The small number of recurrence cases does not allow for potential correlations with demographics and risk factors to be revealed.
The number of patients with stage 1 grade 3 cancers was small, making this category unsuitable for deriving definite conclusions. Overall, this study mainly aimed at examining low-grade, stage 1 cancer recurrence, and the value of routine traditional follow-ups.
Our study has shown a low recurrence rate for stage 1, grade 1, and grade 2 endometrioid endometrial adenocarcinoma, in line with the existing literature. Asymptomatic recurrences were not identified during routine follow-up appointments, despite a considerable amount of resources invested in the hospital follow-up appointments and clinical examinations. Our study supports the implementation of a stratified follow-up strategy with the understanding that larger studies are required in view of the low recurrence rate in early endometrial cancer.
No potential conflict of interest relevant to this article was reported.
This study does not require approval of the Institutional Review Board because no patient identifiable data is contained in this article. The study was performed in accordance with the principles of the Declaration of Helsinki.
Written informed consent and the use of images from patients are not required for the publication.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
The authors would like to thank Paula Lennon, Catherine Marling, Louise Dann, Katie Ayris, and Lois Delcher for collecting the data and note retrieval.
Study flow chart of the 328 women with stage 1 endometrioid adenocarcinoma of the endometrium. a)One patient’s original pathology report was upgraded to grade 2 after recurrence; b)One woman with vault recurrence had lung metastasis at the time of diagnosis of recurrence.
Characteristics of 299 women with surgically treated stage 1 endometrial cancer at Queen’s hospital, from January 2008 to December 2016
Characteristic | Value |
---|---|
Parity | |
Nulliparous | 54 (18.1) |
Parous | 236 (78.9) |
Unknown | 9 (3) |
Menopausal status | |
Pre-menopausal | 36 (12.1) |
Post-menopausal | 259 (86.6) |
Unknown | 4 (1.3) |
BMI>30 | |
Yes | 164 (54.8) |
No | 71 (23.7) |
Unknown | 55 (21.5) |
Diabetic | |
Yes | 57 (19.1) |
No | 197 (65.9) |
Unknown | 40 (15) |
Hypertensive | |
Yes | 161 (53.8) |
No | 111 (37.1) |
Unknown | 28 (9.1) |
History of breast cancer | 15 (5.0) |
Use of tamoxifen | 11 (3.7) |
HRT | |
Current use of HRT | 12 (4.0) |
Past use of HRT | 25 (8.4) |
Never used | 164 (44.8) |
Non-applicable | 36 (12.0) |
Unknown | 92 (30.8) |
Presentation of original disease | |
Post-menopausal bleeding | 231 (77.3) |
Irregular bleeding/menorrhagia | 34 (11.4) |
Vaginal discharge | 7 (2.3) |
Incidental finding | 7 (2.3) |
Weight loss | 2 (0.6) |
Abdominal pain | 3 (1.0) |
Unknown | 15 (5.1) |
Stage | |
1a | 199 (66.5) |
1b | 100 (33.5) |
Grade | |
1 | 219 (73.2) |
2 | 64 (21.4) |
3 | 16 (5.4) |
Primary surgery | |
Laparoscopic hysterectomy & bilateral salpingo-oophorectomy | 147 (49.2) |
Abdominal hysterectomy & bilateral salpingo-oophorectomy | 150 (50.1) |
Vaginal hysterectomy +second procedure bilateral salpingo-oophorectomy | 2 (0.7) |
Adjuvant treatment | |
Intravaginal radiotherapy | 64 (21.4) |
External beam radiotherapy | 6 (2.0) |
Intravaginal and external radiotherapy | 8 (2.7) |
Intravaginal radiotherapy and chemotherapy |
1 (0.3) |
Chemotherapy |
1 (0.3) |
None | 217 (72.6) |
Radiotherapy declined by patient | 1 (0.3) |
Patient unfit for radiotherapy | 1 (0.3) |
Values are presented as number (%).
BMI, body mass index; HRT, hormone replacement therapy.
Patient had presumed involved pelvic lymph node and received adjuvant chemo-radiotherapy;
Patient had concurrent ovarian cancer and received adjuvant chemotherapy, despite grade 1 stage 1a endometrial cancer.
Recurrences in stage 1 endometrial cancer over a 6-year period (January 2008 to December 2016) at Queen’s hospital
Patient (age at diagnosis) | Primary stage | Primary grade | Primary treatment | Adjuvant treatment | Recurrence presentation | Time from surgery to recurrence (mo) | Treatment for recurrence | Status at last follow up |
---|---|---|---|---|---|---|---|---|
1 (81 years) | 1a | 1 |
TAH/BSO |
None | 1st recurrence: vaginal bleeding due to vault recurrence | 7 | Colpectomy, external beam radiation and brachytherapy | Alive and disease free |
2nd recurrence: right groin mass | 35 | Radical excision of groin mass, Provera | ||||||
2 (88 years) | 1a | 3 | TLH/BSO |
None |
Shortness of breath, pleural effusion and lung metastases | 5 | Palliative Died of recurrence | |
3 (69 years) | 1a | 1 | TAH/BSO |
None | 1st recurrence: vaginal bleeding due to vault recurrence | 10 | External beam radiation and brachytherapy | Died of recurrence |
2nd recurrence: vaginal and rectal bleeding | 28 | Pelvic exenteration and chemotherapy | ||||||
4 (63 years) | 1a | 1 | TLH/BSO |
None | Severe hip pain due to bone metastases with enlarged lymph nodes on ultrasound | 44 | Palliative, biopsy not possible | Died of recurrence |
5 (74 years) | 1b | 1 | TAH/BSO |
Intravaginal radiotherapy | Abdominal pain, bloating and fatigue, CT showed enlarged pelvic lymph nodes, pelvic peritoneal mass and hydroureter | 14 | Chemotherapy | Died of recurrence |
6 (77 years) | 1b | 1 | TLH/BSO |
Intravaginal radiotherapy | Jaundice and liver metastases | 14 | Palliative | Died of recurrence |
7 (58 years) | 1b | 2 | TAH/BSO |
None |
1st recurrence: vaginal bleeding due to vault recurrence | 22 | Colpectomy and intravaginal radiotherapy | Died of recurrence |
2nd recurrence: rectal bleeding, weight loss, recurrence with rectal mass and liver metastases | 54 | Palliative | ||||||
8 (72 years) | 1b | 2 | TLH/BSO |
Intravaginal radiotherapy | Shortness of breath on exertion, imaging showed solitary lung metastasis | 50 | Left upper lobectomy and Letrozole | Alive and disease free |
9 (68 years) | 1b | 2 | TAH/BSO |
Intravaginal radiotherapy | Vaginal bleeding | 60 | Unknown | Died-unknown cause |
10 (68 years) | 1a | 1 | TAH/BSO |
None | Admitted with stroke Recurrence identified on CT in the form of pelvic peritoneal disease | 57 | Palliative care Megestrol and Zoladex PS: 3 | Alive |
11 (60 years) | 1a | 1 | TAH/BSO |
Incidental, MRI for hip pain showed vault recurrence, CT showed lung metastasis | 31 | Palliative chemotherapy | Alive |
Tumor size is the largest of the three dimensions documented in histopathological examination reports. Cytological examination of peritoneal washings was negative for malignant cells in all cases.
TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; LVSI, Lymphovascular space invasion; TLH, total laparoscopic hysterectomy; CT, computed tomography; PS, performance score; MRI, magnetic resonance imaging.
The original pathology report was upgraded to grade 2 after recurrence;
Patient declined adjuvant radiotherapy after surgery;
Originally radiotherapy withheld due to several comorbidities.